Comparing Laparoscopic Partial Splenectomy to Standard Splenectomy for Patients with Liver Cirrhosis and Hypersplenism

What this Trial Is About

This research aims to compare immune function changes in patients with liver cirrhosis who undergo laparoscopic partial splenectomy to see if this surgery can improve immune function and patient outcomes. The study focuses on patients with cirrhosis and hypersplenism, evaluating whether preserving part of the spleen during surgery offers benefits over full spleen removal. Patients are randomly assigned to one of two groups one receiving a standard laparoscopic splenectomy where the entire spleen is removed, and the other undergoing laparoscopic partial splenectomy that preserves some blood vessels and spleen tissue. All surgeries are done by the same team, with patients receiving standardized postoperative care and treatments. Monitoring occurs before surgery and at 7 days, 1, 3, 6, and 12 months afterward, including blood tests, liver function, immune markers, and blood flow in relevant veins. Special liver function tests using indocyanine green are done at 3, 6, and 12 months. Participants will have regular follow-up visits with blood tests measuring immune markers, blood cell counts, hemoglobin levels, and blood flow and vessel size in portal and splenic veins. Researchers will monitor for complications such as portal vein thrombosis up to 12 months post-surgery. The main outcomes are changes in immune markers and blood flow at 6 months, with additional measures tracked at other time points up to one year. The study lasts at least 12 months post-operation for thorough assessment.

Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients